Company / Operating Cash Flow
Viridian Therapeutics, Inc.\DE Operating Cash Flow History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Operating Cash Flow
-$276.4M
FY2025
5-year range
-$276.4M / -$54.6M
FY2021-FY2025
Trend
-19.0%
vs FY2024
Sector context
#188 of 216
Health Care
What the data says
Viridian Therapeutics, Inc.\DE's operating cash flow of -$276M is lower than 87% of companies in the Health Care sector (FY2025). Operating Cash Flow has declined for 5 consecutive years, from -$30M in FY2020 to -$276M in FY2025.
Based on SEC 10-K filings.
-$276M in FY2025.
Declined from -$184M to -$276M over the past 2 years.
Health Care sector context is included.
Operating Cash Flow over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
Bottom 13% in Health CareTop 87% of 216This company -$276.4M Sector average $658.7M
▼
-142.0% below sector average
Key checks
Key Insights
- Viridian Therapeutics, Inc.\DE's operating cash flow has declined for 5 consecutive years.
- In FY2025, operating cash flow decreased 19.0% year-over-year.
- Ranks #188 out of 216 companies in the Health Care sector.
- Peak operating cash flow was recorded in FY2016.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score 1.11 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Operating Cash FlowValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | -$276.4M | -19.0% |
| FY2024 | -$232.3M | -26.1% |
| FY2023 | -$184.2M | -96.3% |
| FY2022 | -$93.8M | -71.9% |
| FY2021 | -$54.6M | -83.3% |
| FY2020 | -$29.8M | +17.4% |
| FY2019 | -$36.1M | -34.3% |
| FY2018 | -$26.8M | +4.7% |
| FY2017 | -$28.2M | -90.9% |
| FY2016 | -$14.8M | -113.9% |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026